First-Line Treatment for Arthritis in Rheumatic Fever
Aspirin (acetylsalicylic acid) at high anti-inflammatory doses is the first-line treatment for the migratory polyarthritis of acute rheumatic fever, with a typical dosing range of 75–100 mg/kg per day in children or 4–6 g per day in adults, continued for 4–6 weeks. 1
Rationale for Aspirin as First-Line Therapy
The arthritis of acute rheumatic fever is highly responsive to salicylates, with prompt and dramatic improvement typically occurring within 24–48 hours of initiating therapy—a response so characteristic that it serves as a diagnostic clue supporting the diagnosis of rheumatic fever. 1, 2, 3
High-dose aspirin provides both analgesic and anti-inflammatory effects necessary to control the inflammatory polyarthritis; analgesic doses alone (up to 3,900 mg per day) do not produce adequate anti-inflammatory activity. 4
The migratory polyarthritis of rheumatic fever is self-limited, lasting approximately 4 weeks even without therapy, but treatment with aspirin markedly accelerates symptom resolution and improves patient comfort. 1
Dosing Protocol
Pediatric dosing: 75–100 mg/kg per day divided into 4–6 doses, continued for 4–6 weeks. 1, 5
Adult dosing: 4–6 g per day in divided doses, maintained for a sustained period to achieve anti-inflammatory effect. 2, 4
The dramatic response to aspirin within 24–48 hours helps distinguish acute rheumatic fever from other causes of polyarthritis; lack of response should prompt reconsideration of the diagnosis. 1, 2
Important Safety Considerations and Monitoring
Hepatotoxicity is the most common serious adverse effect, occurring in approximately 30% of patients receiving high-dose aspirin therapy; monitor liver transaminases regularly during treatment. 5
Gastrointestinal irritation affects a significant proportion of patients and may require dose adjustment or temporary discontinuation. 5
Salicylism (tinnitus, hearing loss, hyperventilation) can occur with high-dose therapy and necessitates dose reduction. 5
Mild, transient abnormalities in renal function (51% of patients) and hepatic function (64% of patients) may occur as part of the rheumatic fever disease process itself, independent of aspirin therapy. 2
Alternative First-Line Option When Aspirin Is Not Tolerated
Tolmetin (25 mg/kg per day) is equally effective as aspirin for treating the arthritis of rheumatic fever and produces the same rate of symptom resolution, but with a significantly lower incidence of adverse effects—no hepatotoxicity, gastric irritation, or salicylism was observed in clinical trials. 5
Tolmetin should be considered particularly in patients who cannot tolerate aspirin or in whom aspirin is contraindicated. 5
Critical Pitfall to Avoid
Do not withhold or delay aspirin therapy if acute rheumatic fever is suspected based on clinical criteria, as the dramatic response to salicylates is both therapeutic and diagnostically informative; however, ensure that cardiac evaluation with echocardiography is performed immediately, as carditis determines long-term prognosis and prophylaxis duration. 1
Anti-inflammatory agents provide symptomatic relief but do not prevent rheumatic heart disease; therefore, concurrent initiation of penicillin prophylaxis is mandatory to eradicate residual streptococcal infection and prevent recurrent episodes. 3, 6
Duration of Therapy
Continue aspirin (or tolmetin) for 4–6 weeks to cover the typical self-limited course of rheumatic fever arthritis. 1, 5
Therapy may be extended if symptoms persist, but prolonged courses increase the risk of adverse effects. 5
Concurrent Management Priorities
Immediate penicillin therapy (penicillin V 250 mg orally twice daily for 10 days) must be initiated to eradicate any residual group A streptococcal infection, followed by continuous long-term secondary prophylaxis. 6
Echocardiography should be performed in all cases to detect subclinical carditis, as cardiac involvement determines the duration of secondary prophylaxis (ranging from 5 years to lifelong depending on severity). 1, 6